AIMD Ainos, Inc.
USHealthcareAs of 2026-07-10 13:11
Why AIMD matters now
Ainos, Inc. (AIMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.86 with -2.62% on the session and $8.4M in market capitalization; recent performance reads 1-month +18.06% and YTD +11.59%.
The latest financial table shown here is Q1 2026, with revenue of $161.00, net income of $-2.5M, and EPS of $-0.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.9%.
The latest indexable market news headline is "VASRO Research Highlights Ainos' Expansion of Smell AI Into Patient-Level Breath Intelligence" from Accesswire.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes chiang yao-chung filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.94
P/S
457.50
EV/EBITDA
-2.28
DCF Value
$-2.65
FCF Yield
-52.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-26296.8%
Operating Margin
-72393.5%
Net Margin
-76996.2%
ROE
-160.6%
ROA
-63.2%
ROIC
-63.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $161.00 | $-2.5M | $-0.41 |
| Q4 2025 | $11.1K | $-4.5M | $-0.85 |
| FY 2025 | $124.2K | $-14.8M | $-3.46 |
| Q3 2025 | $2.2K | $-2.9M | $-0.64 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.43
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.